ストックスクリーナーアプリを入手
18.95
2.05%
0.38
前日終値:
$18.57
開ける：
$18.52
24時間の取引高:
121.16K
Relative Volume:
0.73
時価総額：
$644.61M
収益：
-
当期純損益:
$-81.05M
株価収益率:
-7.224
EPS:
-2.6232
ネットキャッシュフロー:
$-68.97M
1週間 パフォーマンス:
-2.92%
1か月 パフォーマンス:
-20.04%
6か月 パフォーマンス:
-17.61%
1年 パフォーマンス:
+6.10%
1日の値動き範囲:
$18.41
$19.04
1週間の範囲:
$17.89
$20.37
52週間の値動き範囲:
$14.35
$36.37
Arrivent Biopharma Inc Stock (AVBP) Company Profile
AVBP を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
AVBP
Arrivent Biopharma Inc
|
18.95 | 644.61M | 0 | -81.05M | -68.97M | -2.6232 |
|
VRTX
Vertex Pharmaceuticals Inc
|
492.69 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
637.36 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
589.15 | 35.93B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
268.46 | 34.75B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
267.39 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Arrivent Biopharma Inc Stock (AVBP) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-03-20 | 開始されました | B. Riley Securities | Buy |
| 2025-03-10 | 開始されました | Guggenheim | Buy |
| 2024-07-22 | 開始されました | Oppenheimer | Outperform |
| 2024-04-30 | 開始されました | H.C. Wainwright | Buy |
| 2024-02-20 | 開始されました | Citigroup | Buy |
| 2024-02-20 | 開始されました | Goldman | Buy |
| 2024-02-20 | 開始されました | Jefferies | Buy |
すべてを表示
Arrivent Biopharma Inc (AVBP) 最新ニュース
Charles Schwab Investment Management Inc. Has $5.50 Million Stake in ArriVent BioPharma, Inc. (NASDAQ:AVBP) - Defense World
Brokers Offer Predictions for AVBP Q1 Earnings - Defense World
Brokerages Set ArriVent BioPharma, Inc. (NASDAQ:AVBP) Target Price at $39.40 - Defense World
ArriVent BioPharma (NASDAQ:AVBP) Upgraded at B. Riley - Defense World
B.Riley sets $37 target on ArriVent stock, initiates with Buy - Investing.com Canada
ArriVent Lead Drug Candidate Shows Promise In Lung Cancer Type, Analyst Sees Over 50% Upside - Benzinga India
This Microsoft Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday - Benzinga
B. Riley Initiates ArriVent BioPharma at Buy With $37 Price Target -March 20, 2025 at 07:13 am EDT - Marketscreener.com
ArriVent Biopharma initiated with a Buy at B. Riley - TipRanks
ArriVent BioPharma (AVBP) Projected to Post Quarterly Earnings on Thursday - Defense World
ArriVent BioPharma (AVBP): Among the Best Short Squeeze Stocks to Buy According to Analysts - Insider Monkey
10 Best Short Squeeze Stocks to Buy According to Analysts - Insider Monkey
ArriVent BioPharma reports FY results - MSN
(AVBP) Technical Pivots with Risk Controls - Stock Traders Daily
ArriVent BioPharma appoints PwC as new auditor - Investing.com India
ArriVent BioPharma appoints PwC as new auditor By Investing.com - Investing.com South Africa
ArriVent BioPharma (NASDAQ:AVBP) Now Covered by Analysts at Guggenheim - Defense World
Oppenheimer starts ArriVent BioPharma at outperform - MSN
Guggenheim starts ArriVent Biopharma with a Buy on firmonertinib potential - TipRanks
Financial Contrast: ArriVent BioPharma (AVBP) and The Competition - Defense World
ArriVent BioPharma (NASDAQ:AVBP) Earns “Buy” Rating from HC Wainwright - Defense World
Here's What Could Help ArriVent BioPharma, Inc. (AVBP) Maintain Its Recent Price Strength - MSN
H.C. Wainwright maintains Buy on ArriVent shares, $39 target By Investing.com - Investing.com Canada
ArriVent BioPharma Reports 2024 Financial Results and Key Achievements - MSN
H.C. Wainwright maintains Buy on ArriVent shares, $39 target - Investing.com India
Rhumbline Advisers Purchases 3,069 Shares of ArriVent BioPharma, Inc. (NASDAQ:AVBP) - Defense World
FY2025 EPS Estimates for AVBP Reduced by Lifesci Capital - Defense World
New York State Common Retirement Fund Boosts Holdings in ArriVent BioPharma, Inc. (NASDAQ:AVBP) - Defense World
ArriVent BioPharma Reports 2024 Financial Results and Progress - MSN
(AVBP) Investment Report - Stock Traders Daily
Lepu Biopharma Co., Ltd. Announces Update on New Drug Application of MRG003 -March 03, 2025 - Marketscreener.com
ArriVent BioPharma, Inc. SEC 10-K Report - TradingView
ArriVent BioPharma Reports Full Year 2024 Financial Results - The Manila Times
Arbutus Biopharma Appoints Lindsay Androski as CEO Amid Leadership Restructuring - MyChesCo
IPOs Numbers Rise In 2024, But Dwindling Returns Could Diminish Potential In 2025 - Scrip
Where are the Opportunities in (AVBP) - Stock Traders Daily
ArriVent BioPharma, Inc. (NASDAQ:AVBP) Short Interest Update - MarketBeat
Mirae Asset Global Investments Co. Ltd. Makes New Investment in ArriVent BioPharma, Inc. (NASDAQ:AVBP) - Defense World
Mirae Asset Global Investments Co. Ltd. Purchases Shares of 1,123 ArriVent BioPharma, Inc. (NASDAQ:AVBP) - Armenian Reporter
How To Trade (AVBP) - Stock Traders Daily
Short Interest in ArriVent BioPharma, Inc. (NASDAQ:AVBP) Expands By 13.1% - MarketBeat
Deal Watch: Novo Nordisk, IMMvention To Partner On Sickle Cell Disease - News & Insights
Asia’s NewCo Model, FDA tipping point, Vertex’s pain drug: a BioCentury podcast - BioCentury
ArriVent BioPharma, Inc. (NASDAQ:AVBP) Shares Bought by JPMorgan Chase & Co. - Defense World
(AVBP) Trading Signals - Stock Traders Daily
The NewCo boom signals China’s galloping speed of innovation - BioCentury
Abbvie seeks molecular glue degraders from Neomorph - BioCentury
ArriVent in Newtown Square Sees Big Potential in New Cancer Drug - DELCO.Today
ArriVent BioPharma Secures Global Rights to MRG007 in Strategic Deal with Lepu Biopharma - MSN
IPO excitement heats up as Metsera targets $1.8B valuation, Aurion joins queue - FirstWord Pharma
Equities Analysts Set Expectations for AVBP Q1 Earnings - Defense World
Arrivent Biopharma Inc (AVBP) 財務データ
収益
当期純利益
現金流量
EPS
0.39%
0.34%
大文字化:
|
ボリューム (24 時間):